Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A comparison of the inflammatory control of asthma provided by one inhalation of Symbicort Turbuhaler 160/4.5 microg/inhalation b.i.d. plus as-needed versus one inhalation of Symbicort Turbuhaler 320/9 microg/inhalation b.i.d. + one inhalation of Pulmicort Turbuhaler 400 microg/dose b.i.d. plus terbutaline Turbuhaler 0.4 mg/inhalation as-needed. A 12-month, randomised, double-blind, parallel-group, active controlled, multinational, phase III B study in adult patients with asthma, EOS

Next Previous
Trial Profile

A comparison of the inflammatory control of asthma provided by one inhalation of Symbicort Turbuhaler 160/4.5 microg/inhalation b.i.d. plus as-needed versus one inhalation of Symbicort Turbuhaler 320/9 microg/inhalation b.i.d. + one inhalation of Pulmicort Turbuhaler 400 microg/dose b.i.d. plus terbutaline Turbuhaler 0.4 mg/inhalation as-needed. A 12-month, randomised, double-blind, parallel-group, active controlled, multinational, phase III B study in adult patients with asthma, EOS

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Budesonide/formoterol (Primary) ; Budesonide; Terbutaline
  • Indications Asthma
  • Focus Pharmacodynamics
  • Sponsors AstraZeneca

    • Most Recent Events

    • 11 Jan 2008 Status changed from in progress to completed.
    • 17 Nov 2006 Status change
    • 22 Nov 2005 New trial record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top